Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting
**Background:** The use of androgen receptor signaling inhibitors, including apalutamide, in combination with androgen deprivation therapy is recommended for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). **...
Saved in:
Main Authors: | Benjamin H. Lowentritt, Carmine Rossi, Erik Muser, Frederic Kinkead, Bronwyn Moore, Patrick Lefebvre, Dominic Pilon, Shawn Du |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2024-08-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.121233 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
by: Rahul Aggarwal, et al.
Published: (2022-01-01) -
Mark Rothko: Untitled (Black on Maroon).
by: Rachel Barker, et al.
Published: (2018-12-01) -
Learning from Black Theology
by: Basil Moore
Published: (2018-10-01) -
'Black Rio! Black Power!'
by: Lucilene Alencar das Dores, et al.
Published: (2025-02-01) -
A Case of Definitive Therapy for Localised Prostate Cancer: Report of a Urological Nightmare
by: Andreas Sommerhuber, et al.
Published: (2012-01-01)